Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

C4X Discovery up research spending as programme progresses

C4X has an an ambition to increase the number of pipeline programmes more than threefold by 2019
C4X Discovery up research spending as programme progresses
C4X upped its spending on reserach

C4X Discovery Holdings PLC (LON:C4XD) saw losses more than double as the cost of research rose sharply.

The drug discovery company saw loss after tax increase to £2.7mln in the six months ended January 2016, compared to £1mln the previous period.

“Research and development expenses at £2.7m for the six months ended 31 January 2016 showed a significant increase compared with the equivalent prior period,” said executive chairman Clive Dix.

It reflected progress within its development pipeline, particularly the progression of the Orexin programme, its treatment for addictive disorders.

Operating losses were £3.4mln, compared to a loss of £1.2mln.

 “With an ambition to increase the number of pipeline programmes more than threefold by 2019, we believe the group is well positioned to deliver future value to shareholders,” said Dix.

Shares stood at 103p at market close Wednesday.

View full C4XD profile

C4X Discovery Holdings plc Timeline

Related Articles

1-Operation.jpg
April 12 2016
Deltex’s overseas sales are booming but its previously dominant NHS revenues are dropping off
Harley Street London street sign
May 27 2016
The cancer treatment specialist has received funding to bring its breakthrough therapy to London.
Benjamin Franklin wearing a medical mask
March 24 2016
Constellation has identified a significant market opportunity in healthcare billing management.

© Proactive Investors 2016

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.